Kyle Jenne

Kyle Jenne discloses dealings in 2 companies, chiefly Ionis Pharmaceuticals Inc and Akcea Therapeutics, Inc. In total, 15 filings cover trades dated from 21 October 2019 to 16 April 2026.

Every open-market trade on record is a sale: 7 sales worth €3.0M. Outside the open market, there are 2 share grants and 5 option exercises. Since January 2026: no purchases and 4 sales on the market.

The latest filing, published on 17 April 2026, reports an option exercise in Ionis Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.